8-K current report · filed Sep 10, 2026

Axogen, Inc. (AXGN) 8-K Current Report: September 10, 2026

Item 1.01Item 7.01Item EX-99.1Item EX-99.2Item EX-99.3AXGN overview

Short answer

Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products.

Axogen, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products
  • Funding planned through public offering of 4,910,000 shares at $42.50, with 736,500-share overallotment option
  • Gross offering proceeds of approximately $208.7M before expenses, intended to fund the acquisition
  • Fourth-quarter 2026 closing depends on IP-license consent, note conversion and electronics-business spin-out
  • Integration execution and uncertain commercial benefits create material acquisition risk; no termination fee disclosed

Item 7.01 · Regulation FD Disclosure

  • Merger Agreement announcement signals a proposed strategic transaction for Axogen shareholders
  • Investor presentation provides management’s rationale and transaction details in Exhibit 99.2
  • Offering pricing announcement indicates concurrent capital raising, with terms in Exhibit 99.3

Item EX-99.1 · Exhibit EX-99.1

  • $200M cash acquisition of BioCircuit, subject to customary adjustments and $1.0M post-closing holdback
  • NerveTape™ adds the first FDA-approved sutureless peripheral nerve repair device, broadening Axogen’s addressable market
  • Funding planned through net proceeds from a public common-stock offering, creating potential shareholder dilution
  • Expected fourth-quarter 2026 closing, conditional on customary approvals and BioCircuit electronics-business spin-out
  • Management expects 2027 revenue contribution and first-year accretion to gross margin, adjusted EBITDA margin and adjusted EPS

Item EX-99.2 · Exhibit EX-99.2

  • $200M cash BioCircuit acquisition, subject to customary adjustments, expected to close in Q4 2026
  • Equity offering: $200M base size plus $30M option, substantially funding acquisition consideration and fees
  • BioCircuit adds NerveTape, the first FDA-cleared sutureless nerve-repair device, with ~$24M annualized Q2 2026 revenue
  • BioCircuit reported $11M 2025 revenue, ~80% gross margins, and $11M standalone EBITDA
  • Management expects Year 1 revenue-growth and adjusted-EBITDA-margin accretion, while remaining free-cash-flow positive post-acquisition

Item EX-99.3 · Exhibit EX-99.3

  • Public offering priced at $42.50 per share for 4,910,000 shares, generating expected gross proceeds of $208.7 million
  • Underwriters hold a 30-day option for 736,500 additional shares, creating potential further dilution
  • Substantially all net proceeds earmarked for cash consideration and expenses related to the BioCircuit Technologies acquisition
  • Offering is not conditional on the BioCircuit acquisition, preserving funding but increasing general-purpose capital if the deal fails
  • Expected closing September 11, 2026, subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Axogen, Inc. 8-K filings

Get the next AXGN 8-K as it lands

Follow AXGN for push alerts, or ask the research agent what this filing means.